BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2003 related articles for article (PubMed ID: 29641966)

  • 1. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
    N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
    Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
    Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.
    Wang P; Xu L; Fan Y; Li B; Chen P; Zhang X; Sun Y; Fu J
    Leuk Lymphoma; 2022 Dec; 63(14):3370-3377. PubMed ID: 36239491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
    Pedrosa L; Fernández-Miranda I; Pérez-Callejo D; Quero C; Rodríguez M; Martín-Acosta P; Gómez S; González-Rincón J; Santos A; Tarin C; García JF; García-Arroyo FR; Rueda A; Camacho FI; García-Cosío M; Heredero A; Llanos M; Mollejo M; Piris-Villaespesa M; Gómez-Codina J; Yanguas-Casás N; Sánchez A; Piris MA; Provencio M; Sánchez-Beato M
    Sci Rep; 2021 Jan; 11(1):1886. PubMed ID: 33479306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
    Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
    Xu-Monette ZY; Wei L; Fang X; Au Q; Nunns H; Nagy M; Tzankov A; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Sun X; Han X; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Albitar M; You H; Young KH
    Clin Cancer Res; 2022 Mar; 28(5):972-983. PubMed ID: 34980601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
    Wright GW; Huang DW; Phelan JD; Coulibaly ZA; Roulland S; Young RM; Wang JQ; Schmitz R; Morin RD; Tang J; Jiang A; Bagaev A; Plotnikova O; Kotlov N; Johnson CA; Wilson WH; Scott DW; Staudt LM
    Cancer Cell; 2020 Apr; 37(4):551-568.e14. PubMed ID: 32289277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
    Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
    Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
    Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
    Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
    Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
    Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
    Nowakowski GS; Czuczman MS
    Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
    Dubois S; Viailly PJ; Mareschal S; Bohers E; Bertrand P; Ruminy P; Maingonnat C; Jais JP; Peyrouze P; Figeac M; Molina TJ; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Salles G; Tilly H; Leroy K; Jardin F
    Clin Cancer Res; 2016 Jun; 22(12):2919-28. PubMed ID: 26819451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 17. Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
    Frauenfeld L; Castrejon-de-Anta N; Ramis-Zaldivar JE; Streich S; Salmerón-Villalobos J; Otto F; Mayer AK; Steinhilber J; Pinyol M; Mankel B; Ramsower C; Bonzheim I; Fend F; Rimsza LM; Salaverria I; Campo E; Balagué O; Quintanilla-Martinez L
    Blood Adv; 2022 Apr; 6(7):2361-2372. PubMed ID: 34654055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.
    Lacy SE; Barrans SL; Beer PA; Painter D; Smith AG; Roman E; Cooke SL; Ruiz C; Glover P; Van Hoppe SJL; Webster N; Campbell PJ; Tooze RM; Patmore R; Burton C; Crouch S; Hodson DJ
    Blood; 2020 May; 135(20):1759-1771. PubMed ID: 32187361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.
    Meriranta L; Pasanen A; Alkodsi A; Haukka J; Karjalainen-Lindsberg ML; Leppä S
    Blood Adv; 2020 Aug; 4(15):3742-3753. PubMed ID: 32780847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.